ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer VIEW MORE >>

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib for the treatment of patients with EGFR-mutant non–small cell lung cancer who have progressed after treatment with osimertinib alone.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.